LIVE

PLSE

Pulse Biosciences, Inc.

PLSE

NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $2.0B

$29.25

+3.25%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$12.56 - $31.00

P/E

-26.83

Fwd P/E

-17.62

Beta

1.66

Div Yield

0.00%

Avg Vol

339.2K

Shares Out

68.0M

Mkt Cap

$2.0B

Price action

Price chart

Up 84.9% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary Nano-Pulse Stimulation technology with strong patent protection
  • Tunable, software-enabled platform enabling multiple clinical applications
  • Non-thermal cellular ablation preserving adjacent tissue integrity
  • First-mover advantage in bioelectric medicine device category

Bear Case

1 risk

  • Above-average volatility (beta 1.7).

Growth

Strong growth ahead

Expanding clinical applications and regulatory approvals across multiple therapeutic areas

Value

Deep value opportunity - significant discount to Medical Devices peers

Momentum

Hot

+23.2% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 6, 2026

Q2 26 RECAP

MAY 4, 2026

Reported EPS of -$0.27 vs -$0.32 consensus (+15.6% surprise). Revenue of $400.0K vs $250.0K expected (+60.0%). Beat on both top and bottom lines.

EPS beat +15.6%
Rev beat +60.0%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+15.6%

Next: May 6, 2026

Revenue trend · last 8Q

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$86.0K

$264.0K

$401.0K

Margins · last 8Q

Gross

Profit

-4633.7%

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

No analyst coverage on file for this stock yet.

vs Industry

How PLSE stacks vs Medical - Instruments & Supplies

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.